AstraZeneca divests troublesome thyroid cancer drug
This article was originally published in Scrip
Executive Summary
In the latest in a series of divestments of non-core assets by AstraZeneca, it is to sell Caprelsa (vandetanib) – a rare disease medicine – to Sanofi's Genzyme for up to $300m.